KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Treasury Shares: 2021-2024

Historic Treasury Shares for Rigel Pharmaceuticals (RIGL) over the last 4 years, with Dec 2024 value amounting to $387,282.

  • Rigel Pharmaceuticals' Treasury Shares rose 51.73% to $569,106 in Q3 2025 from the same period last year, while for Sep 2025 it was $569,106, marking a year-over-year increase of 51.73%. This contributed to the annual value of $387,282 for FY2024, which is 108.29% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Treasury Shares of $387,282 as of FY2024, which was up 108.29% from $185,938 recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Treasury Shares high stood at $1.1 million for FY2022, and its period low was $185,938 during FY2023.
  • Its 3-year average for Treasury Shares is $558,958, with a median of $387,282 in 2024.
  • Its Treasury Shares has fluctuated over the past 5 years, first skyrocketed by 387.80% in 2022, then plummeted by 83.15% in 2023.
  • Yearly analysis of 4 years shows Rigel Pharmaceuticals' Treasury Shares stood at $226,250 in 2021, then surged by 387.80% to $1.1 million in 2022, then plummeted by 83.15% to $185,938 in 2023, then spiked by 108.29% to $387,282 in 2024.